National Guideline Clearinghouse | Crizotinib for previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene.

full-text ►

National Guideline Clearinghouse | Crizotinib for previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene.



National Institute for Health and Care Excellence (NICE)

February 24, 2014

Guideline Title

Crizotinib for previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene.

Bibliographic Source(s)

National Institute for Health and Care Excellence (NICE). Crizotinib for previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene. London (UK): National Institute for Health and Care Excellence (NICE); 2013 Sep. 55 p. (NICE technology appraisal guidance; no. 296).

Guideline Status

This is the current release of the guideline.